About Bridge Biotherapeutics
Bridge Biotherapeutics is a company based in Seongnam-si (South Korea) founded in 2015 was acquired by Parataxis Capital in June 2025. Bridge Biotherapeutics has raised $10 million across 2 funding rounds from investors including KB Investment, LB Investment and HB Investment. The company has 36 employees as of December 31, 2024. Bridge Biotherapeutics operates in a competitive market with competitors including Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
- Headquarter Seongnam-si, South Korea
- Employees 36 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Parataxis Korea, Inc.
-
Annual Revenue
$1.48 K (USD)-97.82as on Dec 31, 2024
-
Net Profit
-$13.4 M (USD)53.32as on Dec 31, 2024
-
EBITDA
-$12.91 M (USD)53.96as on Dec 31, 2024
-
Total Equity Funding
$10 M (USD)
in 2 rounds
-
Latest Funding Round
$10 M (USD), Series A
Jul 04, 2017
-
Investors
KB Investment
& 6 more
-
Employee Count
36
as on Dec 31, 2024
-
Acquired by
Parataxis Capital
(Jun 20, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bridge Biotherapeutics
Bridge Biotherapeutics is a publicly listed company on the KRX with ticker symbol 288330 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Bridge Biotherapeutics
Unlock access to complete
Unlock access to complete
Funding Insights of Bridge Biotherapeutics
Bridge Biotherapeutics has successfully raised a total of $10M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $10 million completed in July 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bridge Biotherapeutics
Bridge Biotherapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include KB Investment, LB Investment and HB Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund
|
Locked | Locked | Locked | |
|
Growth-stage private equity investments are targeted across multiple sectors.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Bridge Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bridge Biotherapeutics
Investment portfolio details for Bridge Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Bridge Biotherapeutics
Detailed financials for Bridge Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bridge Biotherapeutics Comparisons
Peer comparison for Bridge Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bridge Biotherapeutics
Bridge Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nimbus Therapeutics, Escient Pharmaceuticals, Aclaris Therapeutics, Alpine Immune Sciences and Septerna, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
|
| Locked | Locked | Locked |
CRAC channel inhibitors are developed for inflammatory diseases.
|
Detailed competitors of Bridge Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bridge Biotherapeutics
Complete news archive for Bridge Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bridge Biotherapeutics
Bridge Biotherapeutics was founded in 2015.
Bridge Biotherapeutics is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Bridge Biotherapeutics is a funded company, having raised a total of $10M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Bridge Biotherapeutics is 36.
Annual revenue of Bridge Biotherapeutics is $1.48K as on Dec 31, 2024.
Bridge Biotherapeutics was founded in 2015 in Seongnam-si, South Korea, within the biotechnology sector. Small molecule-based therapeutics are developed by the company for diseases including ulcerative colitis, fibrotic conditions, and cancers. The pipeline features BBT-401, a pellino-1 inhibitor in Phase 2 trials for ulcerative colitis, and BBT-877, an autotaxin inhibitor in Phase 2 trials for idiopathic pulmonary fibrosis. Additional candidates are maintained in preclinical and early development stages.
Bridge Biotherapeutics's top competitors include Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences.
Yes, Bridge Biotherapeutics is publicly traded on KRX under the ticker symbol 288330.
Bridge Biotherapeutics has 7 investors. Key investors include KB Investment, LB Investment, HB Investment, DAOL Investment, and Lifecore Partners.
The ticker symbol of Bridge Biotherapeutics is 288330 on KRX.